US4978657A
(en)
*
|
1981-01-09 |
1990-12-18 |
Roussel Uclaf |
Novel 11β-substituted-19-nor-steroids
|
ZA8231B
(en)
*
|
1981-01-09 |
1982-11-24 |
Roussel Uclaf |
New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
|
FR2528434B1
(fr)
*
|
1982-06-11 |
1985-07-19 |
Roussel Uclaf |
Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
|
FR2522328B1
(fr)
*
|
1982-03-01 |
1986-02-14 |
Roussel Uclaf |
Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
|
FR2640977A2
(en)
*
|
1982-06-11 |
1990-06-29 |
Roussel Uclaf |
New position-11 substituted 19-norsteroids and their application as medicinal products.
|
DE3231828A1
(de)
*
|
1982-08-24 |
1984-03-01 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
17(alpha)-alkinyl-3,3-alkylendioxy-5(alpha),10(alpha)-epoxy-9(11)-estren-17(beta)-ol-derivate, verfahren zu deren herstellung und deren verwendung zur weiterverarbeitung
|
DE3231827A1
(de)
*
|
1982-08-24 |
1984-03-01 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
11ss-aryl-17(alpha)-alkinyl-17ss-hydroxy-4,9(10)- estradien-3-on-derivate, deren herstellung und diese enthaltende pharmazeutische praeparate
|
DE3306121A1
(de)
*
|
1983-02-18 |
1984-09-06 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
11ss-aryl-spirolaktone in der steroidreihe, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische praeparate
|
DE3461090D1
(en)
*
|
1983-02-18 |
1986-12-04 |
Schering Ag |
11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
|
IL68222A
(en)
*
|
1983-03-24 |
1987-02-27 |
Yeda Res & Dev |
Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
|
DE3320580A1
(de)
*
|
1983-06-03 |
1984-12-06 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
D-homo-4,9,16-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
|
FR2549067B1
(fr)
*
|
1983-06-14 |
1985-12-27 |
Roussel Uclaf |
Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
|
FR2548192B1
(fr)
*
|
1983-06-20 |
1985-11-22 |
Roussel Uclaf |
Derives estradieniques radioactifs marques a l'iode, leur procede de preparation et leur application aux dosages radioimmunologiques
|
NO162241C
(no)
*
|
1983-06-14 |
1989-11-29 |
Roussel Uclaf |
Nye, radioaktive estradienderivater merket med jod125, fremgangsmaate ved deres fremstilling og deres anvendelse vedradioimmunologisk undersoekelse og mengdebestemmelse av steroider i biologiske vaesker.
|
DE3446661A1
(de)
*
|
1984-12-18 |
1986-06-19 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Neue 13(alpha)-alkyl-17(beta)-(3-acyloxypropyl)-gonane
|
ES8502612A1
(es)
*
|
1983-06-15 |
1985-02-01 |
Schering Ag |
Procedimiento para la preparacion de 13a-alquilgonanos
|
IT1212835B
(it)
*
|
1983-08-18 |
1989-11-30 |
Lehner Ag |
Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
|
DE3337450A1
(de)
*
|
1983-10-12 |
1985-04-25 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
|
AU572589B2
(en)
|
1983-12-14 |
1988-05-12 |
Upjohn Company, The |
11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
|
DE3347126A1
(de)
*
|
1983-12-22 |
1985-07-11 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
|
FR2566779B2
(fr)
*
|
1984-06-29 |
1987-03-06 |
Roussel Uclaf |
Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
|
US5116830A
(en)
*
|
1984-08-17 |
1992-05-26 |
Sri International |
Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses
|
DE3438500C1
(de)
*
|
1984-10-18 |
1986-05-28 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Verfahren zur Herstellung 11ß-substituierter Δ↑9↑-19-Norsteroide
|
FR2573657B1
(fr)
*
|
1984-11-29 |
1989-05-12 |
Roussel Uclaf |
Produit comprenant une substance antiprogestomimetique et une substance uterotonique
|
AU580843B2
(en)
*
|
1985-02-07 |
1989-02-02 |
Schering Aktiengesellschaft |
11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
|
DE3504421A1
(de)
*
|
1985-02-07 |
1986-08-07 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Neue 11ss-phenyl-gonane, deren herstellung und diese enthaltende pharmazeutische praeparate
|
DE3506785A1
(de)
*
|
1985-02-22 |
1986-08-28 |
Schering AG, Berlin und Bergkamen, 1000 Berlin |
11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
|
GB8513723D0
(en)
*
|
1985-05-31 |
1985-07-03 |
Erba Farmitalia |
11-beta substituted steroids
|
DE3531903A1
(de)
*
|
1985-09-05 |
1987-03-12 |
Schering Ag |
Oxytocin und antigestagen zur einleitung der geburt bzw. zum therapeutischen abbruch der graviditaet
|
DE3533175A1
(de)
*
|
1985-09-13 |
1987-03-19 |
Schering Ag |
Antigestagene zur verschiebung der endometrialen reifung
|
FR2596395B1
(fr)
*
|
1986-03-26 |
1989-05-26 |
Roussel Uclaf |
Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
|
FR2598421B1
(fr)
*
|
1986-05-06 |
1988-08-19 |
Roussel Uclaf |
Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
|
DE3761308D1
(de)
*
|
1986-07-23 |
1990-02-08 |
Akzo Nv |
18-phenylestrane-derivate.
|
DE3625315A1
(de)
*
|
1986-07-25 |
1988-01-28 |
Schering Ag |
11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
|
US4774236A
(en)
*
|
1986-09-17 |
1988-09-27 |
Research Triangle Institute |
17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
|
US5272140A
(en)
*
|
1987-01-23 |
1993-12-21 |
Akzo N.V. |
11-aryl steroid derivatives
|
IE60780B1
(en)
*
|
1987-01-23 |
1994-08-10 |
Akzo Nv |
New 11-aryl steroid derivatives
|
US5446178A
(en)
*
|
1987-03-18 |
1995-08-29 |
Schering Aktiengesellschaft |
Process for preparing 19,11β-bridged steroids
|
DE3708942A1
(de)
*
|
1987-03-18 |
1988-09-29 |
Schering Ag |
19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
|
DE3866410D1
(de)
*
|
1987-04-24 |
1992-01-09 |
Akzo Nv |
11-arylestranderivate und 11-arylpregnanderivate.
|
JPH085909B2
(ja)
*
|
1987-07-24 |
1996-01-24 |
協和醗酵工業株式会社 |
Ucy1003誘導体
|
FR2618783B1
(fr)
*
|
1987-07-30 |
1991-02-01 |
Roussel Uclaf |
Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
|
US5319115A
(en)
*
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
US5208227A
(en)
*
|
1987-08-25 |
1993-05-04 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
ATE85342T1
(de)
*
|
1987-12-12 |
1993-02-15 |
Akzo Nv |
11-arylsteroid-derivate.
|
BE1004905A4
(fr)
*
|
1987-12-30 |
1993-02-23 |
Roussel Uclaf |
Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
|
US4954490A
(en)
*
|
1988-06-23 |
1990-09-04 |
Research Triangle Institute |
11 β-substituted progesterone analogs
|
DE3822770A1
(de)
*
|
1988-07-01 |
1990-01-04 |
Schering Ag |
13-alkyl-11ss-phenylgonane
|
DE3832303A1
(de)
*
|
1988-09-20 |
1990-04-12 |
Schering Ag |
11ss-phenyl-14ssh-steroide
|
FR2643638B1
(fr)
*
|
1989-02-24 |
1991-06-14 |
Roussel Uclaf |
Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
DE3917274A1
(de)
*
|
1989-05-24 |
1990-11-29 |
Schering Ag |
9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
|
DE3921059A1
(de)
*
|
1989-06-23 |
1991-01-10 |
Schering Ag |
11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
|
US5276023A
(en)
*
|
1989-08-08 |
1994-01-04 |
Roussel Uclaf |
19-nor-steroid esters
|
FR2651435A1
(fr)
*
|
1989-09-07 |
1991-03-08 |
Roussel Uclaf |
Nouvelle utilisation de composes anti-progestomimetiques.
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
FR2659233B1
(fr)
*
|
1990-03-06 |
1994-01-21 |
Roussel Uclaf |
Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage.
|
DE4018168A1
(de)
*
|
1990-06-01 |
1991-12-05 |
Schering Ag |
Ausgangsverbindungen fuer die herstellung von 10ss-h-steroiden und ein verfahren zur herstellung dieser ausgangsverbindungen
|
US5407928A
(en)
*
|
1990-08-15 |
1995-04-18 |
Schering Aktiengesellschaft |
11β-aryl-gona-4,9-dien-3-ones
|
JPH0464052U
(fr)
*
|
1990-10-05 |
1992-06-01 |
|
|
US5439913A
(en)
|
1992-05-12 |
1995-08-08 |
Schering Aktiengesellschaft |
Contraception method using competitive progesterone antagonists and novel compounds useful therein
|
CA2100514C
(fr)
*
|
1992-07-29 |
2005-03-29 |
Johannes A. M. Hamersma |
Steroides de type 17-spiromethylene
|
WO1995017192A1
(fr)
*
|
1993-12-22 |
1995-06-29 |
The Salk Institute For Biological Studies |
Procede permettant de reduire la resistance multiple aux anti-cancereux
|
US5681817A
(en)
|
1994-02-04 |
1997-10-28 |
The Medical College Of Hampton Roads |
Treatment of ovarian estrogen dependent conditions
|
FR2718354B1
(fr)
*
|
1994-04-08 |
1996-05-03 |
Roussel Uclaf |
Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
|
DE4415590A1
(de)
*
|
1994-04-28 |
1995-11-02 |
Schering Ag |
Verfahren zur stereoselektiven Einführung einer Alkinylseitenkette an 11ß-Aryl-substituierten 13alpha-Alkylgonan-17-onen
|
US5780220A
(en)
*
|
1994-05-19 |
1998-07-14 |
Trustees Of The University Of Pennsylvania |
Methods and compositions for inhibiting HIV replication
|
US5639598A
(en)
*
|
1994-05-19 |
1997-06-17 |
The Trustees Of The University Of Pennsylvania |
Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
|
DE69500542T2
(de)
*
|
1994-05-19 |
1998-01-02 |
Akzo Nobel Nv |
11,21-Bisphenyl-19-nor-pregnan Derivate
|
US5521166A
(en)
*
|
1994-12-19 |
1996-05-28 |
Ortho Pharmaceitical Corporation |
Antiprogestin cyclophasic hormonal regimen
|
ZA9510926B
(en)
|
1994-12-23 |
1996-07-03 |
Schering Ag |
Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
|
US5929262A
(en)
*
|
1995-03-30 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
|
US5767113A
(en)
*
|
1995-05-10 |
1998-06-16 |
The Salk Institute For Biological Studies |
Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
|
IL118974A
(en)
*
|
1995-08-17 |
2001-09-13 |
Akzo Nobel Nv |
History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
|
US6900193B1
(en)
*
|
1996-05-01 |
2005-05-31 |
The United States Of America As Represented By The Department Of Health And Human Services |
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
|
AU710139B2
(en)
*
|
1996-05-01 |
1999-09-16 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
21-substituted progesterone derivatives as new antiprogestational agents
|
DE19706061A1
(de)
*
|
1997-02-07 |
1998-08-13 |
Schering Ag |
Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
|
DE19745085A1
(de)
*
|
1997-10-11 |
1999-04-15 |
Jenapharm Gmbh |
11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
|
DE19809845A1
(de)
*
|
1998-03-03 |
1999-09-09 |
Jenapharm Gmbh |
S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
|
US6020328A
(en)
*
|
1998-03-06 |
2000-02-01 |
Research Triangle Institute |
20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
KR20010043630A
(ko)
*
|
1998-05-15 |
2001-05-25 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
치매의 치료를 위한 글루코코티코이드 수용체 길항제
|
EP1079859B1
(fr)
|
1998-05-22 |
2010-07-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Molecules bifonctionnelles et therapies basees sur celles-ci
|
US6262042B1
(en)
*
|
1998-05-29 |
2001-07-17 |
Research Triangle Institute |
17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
US5962444A
(en)
*
|
1998-05-29 |
1999-10-05 |
Research Triangle Institute |
17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
AU4701299A
(en)
*
|
1998-06-23 |
2000-01-10 |
Stuart R. Adler |
Therapeutic applications of estrogenic carboxylic acids
|
US20020169205A1
(en)
*
|
1998-09-29 |
2002-11-14 |
Krzysztof Chwalisz |
Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
|
CN1117759C
(zh)
*
|
1999-09-02 |
2003-08-13 |
上海中西药业股份有限公司 |
甾体化合物,其制备方法和其药物组合物及其应用
|
US20030013694A1
(en)
*
|
2001-05-25 |
2003-01-16 |
Jens Hoffmann |
Use and compositions of antiprogestins for treatment of prostate diseases
|
FR2826004B1
(fr)
|
2001-06-13 |
2008-03-28 |
Aventis Pharma Sa |
Procede de preparation de derives estrogenes
|
EP1285927A3
(fr)
|
2001-08-16 |
2005-06-29 |
Schering Aktiengesellschaft |
Utilisation d'antagonistes du récepteur glucocorticoide pour la prévention et traitement des maladies de la fonction reproductive masculine
|
US7326697B2
(en)
|
2002-04-29 |
2008-02-05 |
Corcept Therapeutics, Inc. |
Methods for increasing the therapeutic response to electroconvulsive therapy
|
DE10221034A1
(de)
|
2002-05-03 |
2003-11-20 |
Schering Ag |
17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US7250408B2
(en)
|
2002-12-16 |
2007-07-31 |
Bayer Schering Pharma Ag |
Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
|
FR2850022B1
(fr)
*
|
2003-01-22 |
2006-09-08 |
Centre Nat Rech Scient |
Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
|
AU2004217988C1
(en)
*
|
2003-02-28 |
2010-06-03 |
Southwest Foundation For Biomedical Research |
Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
|
EP1643981A2
(fr)
*
|
2003-06-20 |
2006-04-12 |
Viral Genomix, Inc. |
Compositions antivirales et procedes d'utilisation de ces compositions
|
SI1889198T1
(sl)
|
2005-04-28 |
2015-02-27 |
Proteus Digital Health, Inc. |
Farma-informacijski sistem
|
US20070105828A1
(en)
*
|
2005-08-19 |
2007-05-10 |
Glenmark Pharmaceuticals Limited |
Novel polymorph form M of mifepristone and process for its preparation
|
JP2009508494A
(ja)
|
2005-09-16 |
2009-03-05 |
ラプトール ファーマシューティカル インコーポレイテッド |
Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用
|
JP4382735B2
(ja)
|
2005-10-06 |
2009-12-16 |
独立行政法人科学技術振興機構 |
神経因性疼痛治療剤
|
DE102005059222B4
(de)
*
|
2005-12-08 |
2007-10-11 |
Bayer Schering Pharma Ag |
11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
|
WO2007098388A2
(fr)
*
|
2006-02-17 |
2007-08-30 |
Janssen Pharmaceutica N.V. |
Dérivés oxa-stéroïdes comme modulateurs sélectifs du récepteur progestérone
|
US20070270393A1
(en)
*
|
2006-02-17 |
2007-11-22 |
Theresa Buckley |
Methods and compositions for modulation of sleep cycle
|
DE102006018888A1
(de)
*
|
2006-04-18 |
2007-10-25 |
Bayer Schering Pharma Ag |
Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
|
US9517240B2
(en)
|
2006-09-26 |
2016-12-13 |
The Regents Of The University Of California |
Methods and compositions for cancer prevention and treatment
|
US20100160275A1
(en)
*
|
2006-09-26 |
2010-06-24 |
Lee Eva Y H P |
Methods and compositions for cancer prevention and treatment
|
MX343130B
(es)
|
2006-10-24 |
2016-10-26 |
Repros Therapeutics Inc |
Composiciones y métodos para suprimir la proliferación endometrial.
|
CN101616926A
(zh)
*
|
2007-01-17 |
2009-12-30 |
利普生物药剂公司 |
11-(4-氨基苯基)-19-去甲孕-4,9(10)-二烯-3,20-二酮衍生物的可药用盐
|
HU228636B1
(en)
*
|
2007-06-27 |
2013-04-29 |
Richter Gedeon Nyrt |
Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
DK2398500T3
(da)
|
2009-02-20 |
2019-05-13 |
2 Bbb Medicines B V |
Glutathion-baseret lægemiddelafgivelsessystem
|
ES2942923T3
(es)
|
2009-05-06 |
2023-06-07 |
Laboratory Skin Care Inc |
Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
|
DE102009034362A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
DE102009034367A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
DE102009034366A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
DE102009034526A1
(de)
|
2009-07-21 |
2011-02-10 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
|
DE102009034525A1
(de)
|
2009-07-21 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
DE102010007722A1
(de)
|
2010-02-10 |
2011-08-11 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Progesteronrezeptorantagonisten
|
DE102010007719A1
(de)
|
2010-02-10 |
2011-08-11 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Progesteronrezeptorantagonisten
|
US20130018027A1
(en)
|
2010-03-22 |
2013-01-17 |
Repros Therapeutics Inc. |
Compositions and methods for non-toxic delivery of antiprogestins
|
EP2576582B1
(fr)
|
2010-05-26 |
2019-09-18 |
Corcept Therapeutics, Inc. |
Traitement de la dystrophie musculaire
|
DE102011004899A1
(de)
|
2011-03-01 |
2012-09-06 |
Bayer Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
US20130029953A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Klaus Nickisch |
Progesterone antagonists
|
EP2868320A1
(fr)
|
2013-11-03 |
2015-05-06 |
Flamina Holding AG |
Composition ou groupe de compositions pour le traitement de cellules humaines
|
EP3265127B1
(fr)
|
2015-03-02 |
2024-02-21 |
Corcept Therapeutics, Inc. |
Mifepristone et octreotide pour le traitement du syndrome de cushing chez un patient ayant une tumeur neuroendocrine pancréatique sécrétant l'hormone adrénocorticotrope (acth)
|
AU2016243625B2
(en)
|
2015-03-30 |
2020-09-10 |
Corcept Therapeutics, Inc. |
Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
|
EA035567B1
(ru)
|
2015-05-18 |
2020-07-08 |
Байер Фарма Акциенгезельшафт |
Режим приема селективного модулятора рецептора прогестерона (sprm)
|
CA2994422A1
(fr)
|
2015-08-13 |
2017-02-16 |
Corcept Therapeutics, Inc. |
Procede permettant d'etablir un diagnostic differentiel du syndrome de cushing en fonction de l'hormone adrenocorticotrope (acth)
|
AU2016377702B2
(en)
*
|
2015-12-23 |
2021-03-11 |
Oric Pharmaceuticals, Inc. |
Inhibitors of glucocorticoid receptor
|
WO2017112904A1
(fr)
|
2015-12-23 |
2017-06-29 |
Oric Pharmaceuticals, Inc. |
Inhibiteurs de récepteurs glucocorticoïdes
|
US11208432B2
(en)
|
2015-12-23 |
2021-12-28 |
Oric Pharmaceuticals, Inc. |
Inhibitors of glucocorticoid receptor
|
ES2861524T3
(es)
|
2016-01-19 |
2021-10-06 |
Corcept Therapeutics Inc |
Diagnóstico diferencial del Síndrome de Cushing Ectópico
|
EP3214092A1
(fr)
|
2016-03-04 |
2017-09-06 |
Bayer Pharma Aktiengesellschaft |
Promédicaments du modulateur du récepteur de progesterone (sprm) (11.bêta.,17.bêta.)-17-hydroxy-11-[4-(méthylsulphonyle)phenyle]-17-(pentafluoroéthyl)estra-4,9-dièn-3-one
|
CN111690031B
(zh)
*
|
2016-10-07 |
2021-06-01 |
欧瑞克制药公司 |
糖皮质激素受体抑制剂
|
EP3541394A1
(fr)
*
|
2016-11-17 |
2019-09-25 |
Cytoo |
Inducteurs de l'hypertrophie des muscles du squelette
|
CA3065555A1
(fr)
|
2017-06-20 |
2018-12-27 |
Corcept Therapeutics, Inc. |
Methodes de traitement des tumeurs neuro-epitheliales a l'aide de modulateurs selectifs du recepteur de glucocorticoides
|
CN108070016B
(zh)
*
|
2017-12-29 |
2020-07-07 |
广西万德药业有限公司 |
甾体环氧异构体的循环利用方法
|
JP2022552422A
(ja)
|
2019-10-16 |
2022-12-15 |
コーセプト セラピューティクス, インコーポレイテッド |
選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球/リンパ球比を正常化する方法
|
CA3162636A1
(fr)
|
2019-12-21 |
2021-06-24 |
Andreas G. MORAITIS |
Traitement et diagnostic differentiel entre le syndrome de cushing dependant d'acth et le syndrome de cushing independant d'acth
|
EP4263807A2
(fr)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Traitement de lymphocytes infiltrant les tumeurs
|
KR20220149828A
(ko)
|
2021-04-30 |
2022-11-09 |
삼성전자주식회사 |
반도체 소자
|
WO2023000135A1
(fr)
*
|
2021-07-19 |
2023-01-26 |
Context Biopharma Inc. |
Procédés de fabrication d'onapristone et intermédiaires de celle-ci
|